These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17544572)

  • 1. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.
    Eastham JA; Kattan MW; Fearn P; Fisher G; Berney DM; Oliver T; Foster CS; Møller H; Reuter V; Cuzick J; Scardino P;
    Eur Urol; 2008 Feb; 53(2):347-54. PubMed ID: 17544572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on: local progression among men with conservatively treated localized prostate cancer: results from the transatlantic prostate group.
    Hakenberg OW
    Eur Urol; 2008 Feb; 53(2):354. PubMed ID: 17544570
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
    Kanno H; Umemoto S; Izumi K; Hasumi H; Osada Y; Ohta J; Mikata K; Tuchiya F
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):649-59. PubMed ID: 16768146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
    Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
    J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Gleason DF; Barry MJ
    JAMA; 1998 Sep; 280(11):975-80. PubMed ID: 9749479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of progression after PSA elevation following radical prostatectomy.
    Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
    JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.